We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

Back to rankings

150 hedge funds and large institutions have $1.11B invested in Portola Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more call options, than puts

Call options by funds: $17.1M | Put options by funds: $8.1M

13% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 18

1% less funds holding

Funds holding: 151 → 150 (-1)

1% less capital invested

Capital invested by funds: $1.12B → $1.11B (-$10.9M)

Holders
150
Holders Change
-1
Holders Change %
-0.66%
% of All Funds
3.75%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
18
Increased
52
Reduced
46
Closed
18
Calls
$17.1M
Puts
$8.1M
Net Calls
+$8.95M
Net Calls Change
+$3.95M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$16.9M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13.5M
3
Millennium Management
Millennium Management
New York
+$12M
4
WC
Weatherbie Capital
Massachusetts
+$11.7M
5
PHS
PFM Health Sciences
California
+$11.3M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$20.8M
2
DM
Deerfield Management
New York
-$19.2M
3
Goldman Sachs
Goldman Sachs
New York
-$12.9M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$11.8M
5
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$6.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
51
Sphera Funds Management
Israel
$2.24M +$1.95M +100,000 New
GC
52
Guggenheim Capital
Illinois
$2.2M -$105K -5,372 -5%
BA
53
BlackRock Advisors
Delaware
$2.15M +$11.6K +593 +0.6%
MC
54
Marcus Capital
Illinois
$2.08M +$215K +11,000 +13%
Swiss National Bank
55
Swiss National Bank
Switzerland
$2.02M – – –
CS
56
Candriam SCA
Luxembourg
$1.91M +$178K +9,100 +12%
TA
57
Teachers Advisors
New York
$1.79M -$6.82K -349 -0.4%
D.E. Shaw & Co
58
D.E. Shaw & Co
New York
$1.64M -$2.27M -116,133 -61%
Principal Financial Group
59
Principal Financial Group
Iowa
$1.39M +$189K +9,657 +18%
HCMT
60
Highland Capital Management (Texas)
Texas
$1.28M +$326K +16,700 +42%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$1.24M +$27.6K +1,411 +3%
AA
62
ALPS Advisors
Colorado
$1.22M -$346K -17,693 -25%
Creative Planning
63
Creative Planning
Kansas
$1.19M +$594K +30,393 +135%
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$1.13M – – –
OAM
65
Oxford Asset Management
United Kingdom
$1.12M -$5.18M -265,046 -84%
Fisher Asset Management
66
Fisher Asset Management
Washington
$1.05M -$705K -36,100 -44%
ProShare Advisors
67
ProShare Advisors
Maryland
$1.03M +$77.7K +3,978 +9%
BG
68
BlackRock Group
United Kingdom
$1.03M +$45.5K +2,329 +5%
NFA
69
Nationwide Fund Advisors
Ohio
$1.01M -$33.6K -1,721 -4%
US Bancorp
70
US Bancorp
Minnesota
$920K -$9.77K -500 -1%
California Public Employees Retirement System
71
California Public Employees Retirement System
California
$913K – – –
Macquarie Group
72
Macquarie Group
Australia
$880K – – –
BG
73
Bellevue Group
Switzerland
$808K – – –
MLICM
74
Metropolitan Life Insurance Company (MetLife)
New York
$792K – – –
Manulife (Manufacturers Life Insurance)
75
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$769K +$4.86K +249 +0.7%
1 2
3
4 5

PTLA Hedge Fund Activity: Q4 2016 in Review

150 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q4 2016, worth a combined $1.11B — down 0.97% from $1.12B a quarter earlier.

Fund positioning in PTLA was balanced in Q4 2016: 18 funds opened new positions, 18 closed out, 52 added to existing stakes and 46 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $16.9M. The largest seller was Redmile Group, exiting entirely with an estimated $20.8M sold.

  • 150 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q4 2016, down from 151 in Q3 2016.
  • Funds reported $1.11B of Portola Pharmaceuticals, Inc. stock for Q4 2016, down 0.97% quarter-over-quarter.
  • 18 funds opened new Portola Pharmaceuticals, Inc. positions in Q4 2016 and 18 closed out, a net change of 0 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q4 2016 was Morgan Stanley, an estimated $16.9M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q4 2016 was Redmile Group, an estimated $20.8M sold.

Based on aggregated 13F filings for Q4 2016.